orai-1 Antibody

What is Orai1 and what role does it play in cellular calcium signaling?

Orai1 is a 301 amino acid multi-pass membrane protein that serves as the pore-forming subunit of the calcium release-activated calcium (CRAC) channel. It plays a critical role in the process of store-operated calcium entry (SOCE) . Located at the plasma membrane, Orai1 mediates calcium influx in various cell types, most notably in T-cells, where it is vital for proper immune response . The formation of functional CRAC channels requires both Orai1 on the plasma membrane and STIM1 (stromal interaction molecule 1) on the endoplasmic reticulum, which acts as a calcium sensor . When intracellular calcium stores are depleted, STIM1 senses this change and co-clusters with Orai1, forming active CRAC channels that allow calcium entry into the cell . This calcium influx is essential for numerous cellular processes including T-cell activation, proliferation, and cytokine production . Defects in Orai1 function can lead to severe immunological disorders, highlighting its importance in maintaining proper cellular calcium homeostasis.

How does Orai1 distribution differ across tissue types, and what are the implications for research?

Orai1 shows a distinct tissue distribution pattern, with its transcripts predominantly found in immune cells . This contrasts with other members of the Orai family: Orai2 is mainly expressed in the brain, lungs, spleen, and small intestine, while Orai3 is abundantly present in many solid organs . This differential expression pattern has significant implications for research. When designing experiments targeting Orai1, researchers should consider the tissue specificity to avoid off-target effects or misinterpretation of results. The predominant expression of Orai1 in immune cells makes it a particularly attractive target for immunological research and the development of immunomodulatory therapies. When selecting appropriate experimental models, researchers should account for this tissue-specific expression pattern. For instance, studies focused on T-cell activation or mast cell degranulation would be particularly relevant for Orai1 research, whereas studies on neuronal calcium signaling might need to consider Orai2's role more prominently. This tissue distribution knowledge helps in developing more targeted and effective research approaches for each Orai family member.

What is the relationship between Orai1 and immune cell function?

Orai1 plays a fundamental role in immune cell function, particularly in T-cells and mast cells. In T-cells, calcium influx through CRAC channels (where Orai1 constitutes the pore-forming subunit) occurs following antigen-receptor engagement and is essential for activation, proliferation, and cytokine production . This calcium signaling pathway represents a critical step in the adaptive immune response. Experimental evidence demonstrates that Orai1 knockout mice show reduced T-cell cytokine production and impaired mast cell activation , confirming its essential role in immune function. The critical nature of Orai1 in immune regulation is further highlighted by the observation that ORAI1 homogenous deficiency in humans causes severe combined immunodeficiency (SCID), characterized by significantly impaired or absent T-cell function . Anti-Orai1 antibodies have been shown to inhibit T-cell proliferation and cytokine production in vitro, and demonstrate efficacy in human T-cell-mediated graft-versus-host disease (GvHD) mouse models . These findings collectively establish Orai1 as a central regulator of immune cell function and a potential therapeutic target for modulating immune responses in various pathological conditions.

What criteria should researchers use when selecting an anti-Orai1 antibody for their experiments?

When selecting an anti-Orai1 antibody for research, several critical factors should be evaluated to ensure experimental success. First, researchers must consider the intended application, as different antibodies may be optimized for specific techniques. For example, the Orai1 Antibody (G-2) from Santa Cruz Biotechnology has been validated for western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry with paraffin-embedded sections, and ELISA . Second, epitope specificity is crucial - antibodies targeting different regions of Orai1 (such as extracellular loops versus intracellular domains) may yield different results. The anti-Human Orai1 antibody from Alomone Labs, for instance, targets the second extracellular loop (amino acid residues 203-214) , making it suitable for detecting surface-expressed Orai1 in live cells. Third, species reactivity must match the experimental model - some antibodies like DS-2741a bind specifically to human Orai1 without cross-reactivity to rodent Orai1 . Fourth, researchers should review validation data provided by manufacturers, including western blot images, flow cytometry results, and blocking peptide controls . Finally, consider the antibody format and conjugation options based on experimental needs - many anti-Orai1 antibodies are available in both non-conjugated forms and conjugated to various fluorophores or enzymes for detection purposes . Thorough evaluation of these factors will lead to selection of the most appropriate anti-Orai1 antibody for specific research objectives.

How can researchers verify the specificity of anti-Orai1 antibodies?

Verifying antibody specificity is crucial for obtaining reliable research results when working with anti-Orai1 antibodies. Researchers can employ several complementary approaches to confirm specificity. First, peptide competition assays represent a gold standard method, where pre-incubation of the antibody with its target peptide (such as the Human Orai1 extracellular Blocking Peptide) should eliminate or significantly reduce signal in applications like western blot . Second, comparative analysis using positive and negative control samples is essential - researchers should test the antibody on cell lines known to express Orai1 (like human Jurkat T-cell leukemia cells) versus those with minimal expression or Orai1-knockout models . Third, multiple detection methods should be employed; for example, if an antibody shows expected results in both western blot and flow cytometry, confidence in its specificity increases. Fourth, detection of the correct molecular weight band (~33-35 kDa for unmodified Orai1) in western blot analyses provides additional validation . Fifth, competitive inhibition assays using various peptides (such as those from different Orai family members or orthologs) can help determine cross-reactivity profiles, as demonstrated with DS-2741a . Finally, examining antibody performance in knockout/knockdown systems provides the most definitive evidence of specificity - signals should be absent or significantly reduced in Orai1-deficient samples. Implementation of these rigorous validation strategies ensures that experimental outcomes truly reflect Orai1 biology rather than non-specific interactions.

How should researchers optimize western blot protocols for Orai1 detection?

Optimizing western blot protocols for Orai1 detection requires careful consideration of several technical aspects due to Orai1's nature as a multi-pass membrane protein. First, sample preparation is critical - use fresh samples with protease inhibitors and avoid multiple freeze-thaw cycles that could degrade the protein. For membrane protein extraction, employ specialized lysis buffers containing appropriate detergents (like 1% Triton X-100 or RIPA buffer) to effectively solubilize Orai1. Second, protein denaturation conditions must be optimized - avoid boiling samples, instead heat at 37-50°C for 30 minutes to prevent aggregation common with membrane proteins. Third, gel selection is important - use 10-12% SDS-PAGE gels for optimal resolution of Orai1, which has a molecular weight of approximately 33-35 kDa. Fourth, transfer conditions should be carefully controlled - use PVDF membranes (rather than nitrocellulose) with lower methanol concentrations in transfer buffer to enhance hydrophobic protein transfer. Fifth, blocking solutions should be optimized - test both BSA and non-fat dry milk to determine which provides better signal-to-noise ratio with your specific antibody. Sixth, antibody dilution and incubation must be carefully titrated - start with manufacturer recommendations (typically 1:200 to 1:1000) and optimize as needed . Finally, always include appropriate positive controls (such as Jurkat T-cell lysates) and negative controls (pre-incubation with blocking peptide) to verify specificity, as demonstrated in the western blot analysis protocol from Alomone Labs . These optimizations will help overcome the challenges associated with detecting this multi-pass membrane protein.

What flow cytometry protocols are most effective for detecting surface-expressed Orai1?

Flow cytometry represents a powerful technique for detecting and quantifying surface-expressed Orai1 on intact cells. To achieve optimal results, researchers should implement the following protocol optimizations. First, use antibodies specifically targeting extracellular epitopes of Orai1, such as those recognizing the second extracellular loop (residues 203-214 in human Orai1) . Second, maintain cell viability throughout the procedure, as dead cells can give false positive signals; include a viability dye in your panel. Third, optimize fixation conditions carefully - if fixation is necessary, use a mild fixative like 1-2% paraformaldehyde to preserve epitope accessibility while maintaining membrane integrity. Fourth, blocking is crucial - incubate cells with appropriate blocking buffer containing serum matching the secondary antibody species to minimize non-specific binding. Fifth, antibody titration is essential - determine the optimal concentration of primary antibody (typically starting around 5μg per sample) that gives maximum specific signal with minimal background . Sixth, for indirect detection, select appropriate fluorophore-conjugated secondary antibodies that match your instrument configuration and optimize their concentration. For example, Alomone Labs protocol uses goat-anti-rabbit-FITC for detection . Seventh, always include proper controls, including unstained cells, secondary-only controls, and when possible, blocking peptide controls or Orai1-deficient cells. Finally, when analyzing data, use appropriate gating strategies to identify positive populations, and consider the typically modest shift in fluorescence intensity seen with membrane proteins. This optimized methodology enables reliable detection of surface-expressed Orai1 in various experimental systems.

What are the key considerations for using anti-Orai1 antibodies in immunoprecipitation studies?

Immunoprecipitation (IP) with anti-Orai1 antibodies requires careful optimization to successfully isolate this multi-pass membrane protein and its interacting partners. First, cell lysis conditions must be carefully selected - use non-denaturing detergents (such as digitonin, CHAPS, or NP-40) at concentrations that solubilize membranes while preserving protein-protein interactions. Overly harsh detergents can disrupt the native conformation of Orai1 and its interactions. Second, antibody selection is crucial - choose antibodies specifically validated for IP applications, such as the Orai1 Antibody (G-2) , and verify they recognize the native conformation of the protein. Third, optimize antibody-to-lysate ratios through titration experiments to determine the amount needed for efficient capture without excess antibody that might increase non-specific binding. Fourth, select appropriate beads for antibody immobilization - Protein A/G beads work well for many IgG antibodies, while specialized conjugated agarose beads may offer advantages for specific applications . Fifth, washing conditions represent a critical balance - stringent enough to remove non-specific binders but gentle enough to maintain specific interactions; typically, multiple washes with decreasing salt concentrations are effective. Sixth, elution methods should be chosen based on downstream applications - harsh elution with SDS for maximum recovery and subsequent western blot analysis, or milder methods if maintaining protein activity is required. Finally, always include appropriate controls, such as non-immune IgG matching the species and isotype of the IP antibody, as well as lysates from cells lacking or depleted of Orai1 when possible. These optimized conditions enable successful isolation of Orai1 and its interacting partners for further analysis.

How do anti-Orai1 antibodies modulate immune cell function in experimental disease models?

Anti-Orai1 antibodies demonstrate significant immunomodulatory effects through several mechanisms that collectively suppress immune cell activation and inflammatory responses. First, these antibodies can directly inhibit CRAC channel function by binding to extracellular epitopes of Orai1, thereby blocking calcium influx that is essential for immune cell activation . Second, binding of anti-Orai1 antibodies can induce cellular internalization of the channel, as demonstrated with monoclonal antibodies against human Orai1, effectively removing the calcium channel from the cell surface . Third, by inhibiting calcium signaling, these antibodies suppress T-cell proliferation and cytokine production in response to various stimuli, including T-cell receptor engagement . Fourth, anti-Orai1 antibodies have been shown to inhibit mast cell degranulation, which is relevant for allergic conditions as demonstrated in passive cutaneous anaphylaxis (PCA) models . In disease models, the therapeutic effects are substantial - DS-2741a ameliorated house dust mite antigen-induced dermatitis in human ORAI1 knock-in mice , while other anti-Orai1 monoclonal antibodies demonstrated efficacy in a human T-cell-mediated graft-versus-host disease (GvHD) mouse model . These findings illustrate how anti-Orai1 antibodies can modulate immune responses through direct inhibition of calcium signaling, with potential applications in autoimmune disorders, allergic conditions, and transplantation medicine. The specificity of this approach offers advantages over broad immunosuppressive therapies, potentially minimizing systemic side effects.

What experimental models are available for studying Orai1 function using antibody-based approaches?

Researchers have developed several sophisticated experimental models for studying Orai1 function using antibody-based approaches. First, human ORAI1 knock-in mice represent a valuable model where the extracellular loop domain of mouse Orai1 is replaced with the corresponding human ORAI1 sequence . This model enables testing of human-specific anti-Orai1 antibodies in an in vivo context while maintaining physiological expression patterns. Second, cell-based assays using human ORAI1-overexpressing cell lines provide systems for initial screening and characterization of antibody binding and functional effects . These can be coupled with calcium imaging techniques to directly assess antibody impact on CRAC channel function. Third, ex vivo assays using primary human T-cells or T-cells isolated from humanized mice allow for functional assessment of antibody effects on immune cell activation, proliferation, and cytokine production . Fourth, passive cutaneous anaphylaxis (PCA) models permit evaluation of anti-Orai1 antibody effects on mast cell function and allergic responses in vivo . Fifth, house dust mite antigen-induced dermatitis in human ORAI1 knock-in mice provides a model for studying antibody effects in allergic skin inflammation . Finally, human T-cell-mediated graft-versus-host disease (GvHD) mouse models allow assessment of anti-Orai1 antibody efficacy in a complex immunological setting relevant to transplantation medicine . These diverse experimental models, spanning from molecular and cellular systems to in vivo disease models, provide complementary approaches for comprehensive characterization of anti-Orai1 antibodies and their potential therapeutic applications.

What advantages do antibody-based approaches offer over small molecule inhibitors of Orai1?

Antibody-based approaches to targeting Orai1 offer several distinct advantages over small molecule inhibitors, particularly in research and therapeutic contexts. First, antibodies typically provide superior target specificity compared to small molecules. Anti-Orai1 antibodies can discriminate between highly homologous Orai family members (Orai1, Orai2, and Orai3) and even between species orthologs, as demonstrated by DS-2741a which binds specifically to human Orai1 without cross-reactivity to rodent Orai1 . Second, antibodies can induce receptor internalization, providing a mechanism of action beyond simple channel blockade. This has been demonstrated with anti-Orai1 monoclonal antibodies that lead to cellular internalization of the channel, effectively removing it from the cell surface . Third, antibodies offer extended half-life in vivo compared to small molecules, potentially allowing for less frequent dosing in therapeutic applications. Fourth, the ability to engineer antibody formats provides versatility - from full IgG molecules for therapeutic applications to various conjugated formats (HRP, fluorophores) for research applications . Fifth, antibodies enable complementary research approaches not possible with small molecules, such as immunoprecipitation to identify interaction partners or immunohistochemistry to study tissue distribution. Finally, the development of humanized antibodies, as exemplified by DS-2741a , minimizes immunogenicity risks when translating to human applications. These advantages collectively make antibody-based approaches a valuable complement to small molecule strategies for both fundamental research on Orai1 biology and potential therapeutic development for immune-mediated conditions.

What are common pitfalls in Orai1 detection and how can researchers overcome them?

Detecting Orai1 protein presents several technical challenges that researchers should anticipate and address. First, low endogenous expression levels in many cell types can result in weak signals. To overcome this, researchers can employ signal amplification techniques such as enhanced chemiluminescence (ECL) for western blots or tyramide signal amplification for immunostaining. Additionally, enriching for membrane fractions during sample preparation can concentrate Orai1 proteins. Second, protein degradation during sample handling can significantly reduce detection. Implement rigorous sample preparation protocols including immediate processing, maintaining cold temperatures throughout, and using comprehensive protease inhibitor cocktails. Third, epitope masking can occur due to protein-protein interactions or conformational changes. Try multiple antibodies targeting different epitopes, and consider mild denaturation conditions that maintain antibody recognition while exposing hidden epitopes. Fourth, non-specific binding often leads to high background, especially in flow cytometry and immunohistochemistry. Optimize blocking conditions using a combination of serum, BSA, and non-fat dry milk, and include appropriate controls including blocking peptides . Fifth, membrane protein aggregation during SDS-PAGE can create artifacts. Modify standard protocols by reducing sample heating temperature (37-50°C instead of boiling) and adjusting detergent concentrations. Finally, post-translational modifications may affect antibody recognition. When possible, use multiple antibodies targeting different regions and validate findings using complementary techniques such as mass spectrometry. Implementing these strategies will help overcome the common technical challenges associated with Orai1 detection.

How should researchers validate functional effects of anti-Orai1 antibodies in their experimental systems?

Validating the functional effects of anti-Orai1 antibodies requires a multi-faceted approach to establish specificity and biological relevance. First, calcium imaging represents an essential functional readout, as inhibition of Orai1 should reduce store-operated calcium entry. Researchers should measure intracellular calcium using fluorescent indicators (like Fura-2 or Fluo-4) following store depletion with thapsigargin or ionomycin, both in the presence and absence of the anti-Orai1 antibody. Second, patch-clamp electrophysiology provides direct measurement of CRAC currents and should demonstrate reduced current amplitude with functional antibodies. Third, downstream functional assays specific to the cell type being studied should be employed. For T-cells, this includes measuring activation markers, proliferation, and cytokine production (such as IL-2) in response to stimuli like PMA/ionomycin or anti-CD3/CD28 beads . For mast cells, degranulation assays and histamine release measurements provide relevant functional readouts . Fourth, dose-response relationships should be established to demonstrate concentration-dependent effects. Fifth, specificity controls are critical - including isotype control antibodies of the same species and class, as well as testing effects in Orai1-deficient or knockdown cells where the antibody should show no effect. Sixth, for antibodies targeting extracellular epitopes, competitive inhibition with soluble peptides should reverse functional effects . Finally, researchers should validate findings across multiple cell types and experimental conditions to establish robust and reproducible results. This comprehensive validation approach ensures that observed effects truly represent specific inhibition of Orai1 function.

What controls are essential when using anti-Orai1 antibodies in various experimental applications?

Implementing appropriate controls is essential for ensuring reliable results when using anti-Orai1 antibodies across different experimental applications. First, isotype controls matching the species, class, and subclass of the anti-Orai1 antibody should always be included to distinguish specific binding from Fc-receptor interactions or other non-specific effects. For example, when using DS-2741a (a humanized antibody), the appropriate isotype control IgG should be included in functional assays . Second, peptide competition controls are vital for validating antibody specificity - pre-incubating the antibody with excess blocking peptide corresponding to the target epitope should abolish specific signals in applications like western blotting and immunofluorescence . Third, negative cell controls are crucial - cells known to express minimal or no Orai1 provide important background references, while Orai1 knockout or knockdown samples represent gold-standard negative controls. Fourth, positive cell controls such as Jurkat T-cells or other immune cells with known Orai1 expression help establish expected signal patterns . Fifth, for functional assays, pharmacological controls provide important reference points - calcium chelators (EGTA) can confirm calcium-dependent effects, while established CRAC channel inhibitors (like 2-APB or La3+) provide comparison standards. Sixth, for therapeutic antibodies, target species validation is essential - testing antibodies in systems expressing human versus mouse Orai1 confirms species specificity, as demonstrated with DS-2741a which shows specificity for human but not rodent Orai1 . Finally, method-specific controls (such as secondary-only for immunostaining or empty-vector transfected cells for overexpression systems) should be tailored to each experimental approach. These comprehensive controls collectively ensure that experimental results specifically reflect Orai1 biology rather than artifacts.

How can researchers use anti-Orai1 antibodies to study CRAC channel assembly and regulation?

Anti-Orai1 antibodies provide sophisticated tools for investigating the complex processes of CRAC channel assembly and regulation. First, proximity ligation assays (PLA) using anti-Orai1 antibodies together with anti-STIM1 antibodies enable visualization and quantification of Orai1-STIM1 interactions at the plasma membrane-ER junctions in situ. This technique can reveal spatial and temporal dynamics of channel assembly following store depletion. Second, immunoprecipitation with anti-Orai1 antibodies followed by mass spectrometry analysis can identify novel interaction partners and post-translational modifications that regulate channel function. The Orai1 Antibody (G-2) validated for immunoprecipitation is particularly useful for such applications . Third, super-resolution microscopy combined with extracellular epitope-targeting antibodies allows tracking of Orai1 clustering and diffusion in the plasma membrane during CRAC channel activation. Fourth, antibody-based proximity biotinylation methods (like BioID or APEX) can map the molecular neighborhood of Orai1 in living cells. Fifth, conformation-specific antibodies that preferentially recognize active or inactive Orai1 conformations would provide unique insights into structural rearrangements during channel gating. Sixth, FRET-based approaches using fluorescently-labeled anti-Orai1 Fab fragments can monitor dynamic protein-protein interactions in real time. Finally, engineered antibodies that lock channels in specific conformational states could serve as valuable tools for structural biology studies. These advanced applications of anti-Orai1 antibodies enable researchers to dissect the molecular mechanisms of CRAC channel assembly, stoichiometry, and regulation with unprecedented resolution, advancing our understanding of this critical calcium signaling pathway.

What are the emerging therapeutic applications of Orai1-targeting antibodies beyond autoimmunity?

While autoimmune applications have been at the forefront of Orai1-targeting antibody research, several emerging therapeutic areas show significant promise. First, allergic disorders represent a key opportunity, as demonstrated by DS-2741a's efficacy in house dust mite antigen-induced dermatitis models and the inhibition of mast cell degranulation in passive cutaneous anaphylaxis (PCA) models . The central role of Orai1 in mast cell activation makes conditions like atopic dermatitis, asthma, and food allergies compelling targets. Second, transplantation medicine has shown promise with anti-Orai1 antibodies demonstrating efficacy in graft-versus-host disease (GvHD) models , suggesting potential applications in preventing transplant rejection while avoiding broad immunosuppression. Third, certain cancer immunotherapies could benefit from selective immune modulation with anti-Orai1 antibodies, particularly where targeted suppression of specific T-cell subsets might enhance therapeutic outcomes while minimizing systemic immunosuppression. Fourth, research suggests potential applications in inflammatory pain conditions, as calcium signaling through Orai1 contributes to neuroinflammatory processes. Fifth, antibody-drug conjugates using anti-Orai1 antibodies could selectively target cells with high Orai1 expression, such as certain cancer cells or pathologically activated immune cells. Sixth, certain respiratory conditions with strong T-cell and mast cell components, including aspects of COPD and severe asthma, represent potential applications. These emerging therapeutic directions highlight the versatility of Orai1-targeting antibodies beyond traditional autoimmune applications, leveraging their specificity for calcium signaling modulation across multiple pathological contexts.

How might researchers develop antibodies that selectively target specific Orai1 conformational states?

Developing antibodies that selectively recognize specific Orai1 conformational states represents an advanced frontier in CRAC channel research with significant implications for both basic science and therapeutic applications. First, researchers can employ state-specific immunization strategies, where antigens mimic active or inactive Orai1 conformations. This could involve designing peptides that adopt conformations present only in activated channels, potentially focusing on the second extracellular loop that undergoes conformational changes during gating . Second, phage display technology with conformation-locked Orai1 constructs enables selection of antibodies that specifically bind to particular states. Mutations that stabilize Orai1 in open or closed conformations can serve as selection targets during the screening process. Third, yeast surface display combined with flow cytometry sorting allows isolation of antibody variants with enhanced specificity for particular Orai1 conformations. Fourth, structural biology approaches including cryo-EM and X-ray crystallography provide atomic-level insights into Orai1 conformational states, guiding rational antibody engineering. Fifth, advanced screening methodologies using functional calcium imaging can identify antibodies that not only bind to specific conformations but also modulate channel function in predictable ways - either stabilizing open states (potentially enhancing calcium entry) or closed states (inhibiting calcium entry). Sixth, computational approaches including molecular dynamics simulations and in silico antibody design can accelerate identification of epitopes uniquely exposed in specific channel conformations. These state-selective antibodies would serve as powerful research tools for studying CRAC channel activation mechanisms and potentially as precision therapeutics that modulate channel function in specific contexts rather than simply blocking all activity.